4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.

Pfizer Ventures and Chiesi Ventures returned to back inherited disease therapy developer 4D Molecular Therapeutics, which filed to go public in September.

Returning investors Axel Springer and Purplebricks combined to invest $45.2m in the online real estate brokerage that will fund hiring and product development.

Based on research from academic schools including Princeton, Chicago and Alabama at Birmingham, the oncolytic viral therapy developer has now received more than $80m to date.

The educational game portal, a spinout of Norwegian University of Science and Technology, pulled in $28m as investors also bought $62m of secondary shares.

GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs.

University of Cambridge stem cell differentiation spinout Bit Bio secured $41.5m from investors including Arch Venture Partners to boost its overall funding to $50m.

Tencent-backed telemedicine service Miaoshou Doctor pulled in $84.5m that will support the strengthening of its health insurance provision.

Genomic heart disease drug developer Verve Therapeutics secured funding in a round led by GV, which also led its series A last year.

BCC, Broadway Video, WME and Chernin Group were reportedly among the investors that added $47.7m to the $93m in financing the meditation platform raised in February.